Sanford C. Bernstein
https://www.bernsteinresearch.comSanford C. Bernstein, a division of AllianceBernstein, is a research firm.
View Older Stories View More Recent Stories
-
5 analysts discuss Amazon stock after earnings: You have to spend money to make money
-
5 analysts discuss Apple stock after earnings: 'The best is yet to come'
-
Snap shares plummet as weak outlook intensifies ad competition fears
-
Intel shares slump 26% as turnaround struggle deepens
-
British Airways owner IAG scraps deal to acquire Air Europa
-
Apple is about to report. Here's what to expect
-
Ferrari lifts forecasts on pricier models and personal touches
-
Merck raises outlook for electronics and healthcare, sees improved chip market demand
-
Meta rallies as strong ad revenue cushions AI spending
-
Societe Generale: Second quarter 2024 earnings
-
Bernstein and Argus fuel PayPal optimism with stock rating upgrades
-
TelevisaUnivision Announces CFO Transition
-
Apple likely to post higher revenue as discounts aid iPhone demand in China
-
PayPal's turnaround plan faces challenges from competition, analysts say
-
Qualcomm earnings preview: Here are the key things to watch
-
Bernstein SocGen Group Upgrades PayPal (PYPL) to Outperform - First Time in Nearly Three Years
-
Acadia Realty Trust Reports Second Quarter Operating Results
-
Equitable Holdings Reports Second Quarter 2024 Results
-
Form 13F-HR Richard Bernstein Adviso For: Jun 30
-
Marius Pharmaceuticals Submits KYZATREX® (Testosterone Undecanoate) CIII Capsules for Approval to Health Canada
-
Manatt Adds Health Policy Adviser to D.C. Office
-
Blackbird Launches New Restaurant Payments and Rewards Platform to Improve Merchant Economics and Transform the Guest Experience
-
PECA Labs Adds Joseph E. Bavaria, MD to Board of Directors
-
Bernstein SocGen Group Starts Sartorius AG (SRT3:GR) (SARTF) at Underperform
-
Bernstein SocGen Group Starts Sartorius Stedim Biotech (DIM:FP) (SDMHF) at Underperform
-
Recent sell-off presents an attractive entry point in this stock
-
Financial Advisor Dan Chorney joins UBS in New York City
-
US-listed crypto stocks retreat following Trump-fueled spike
-
Heineken's shares slide as first-half results miss forecasts
-
Intel (INTC), AMD: 'No-man's land?' Q2 earnings preview
-
Is Trump 2.0 all doom and gloom for the renewables sector?
-
Bernstein Cautious on Exact Sciences (EXAS)
-
ALLIANCEBERNSTEIN HOLDING L.P. ANNOUNCES SECOND QUARTER RESULTS
-
Bernstein SocGen Group Reiterates Outperform Rating on Liberty Global (LBTYA)
-
Analysis-End of tax loophole risks dimming Shein's IPO appeal, investors say
-
Under pressure in China, Mercedes trims profit outlook
-
SPIE - Press release - 2024 Half-Year results
-
The Hartford Announces Outstanding Second Quarter 2024 Financial Performance
-
Birkin handbag maker Hermes outshines rivals with big sales jump
-
US fast-food chains' bets on value meal set to face investor scrutiny
-
Manatt Adds Leaders to Enhance Life Sciences and Digital Health Legal and Advisory Practices
-
The Bull-Bear debate on Dell
-
RTX lifts 2024 profit forecast on strength in aviation sector
-
US market proves a headache for global carmakers
-
Stellantis ready to axe brands and fix US problems, CEO says
-
Bel Reports Second Quarter 2024 Results
-
NACTT Trustees Urge Uniform Guidelines for Artificial Intelligence in Consumer Bankruptcy Practices
-
CPC Issues Letter to Fellow XWELL (XWEL) Shareholders
-
CPC Issues Letter to Fellow XWELL, Inc. Shareholders Revealing Intention Behind Recent Schedule 13D Filing & Lawsuit Against Entrenched Board of Directors
-
M8 Pharmaceuticals, an Acino company, Signs Exclusive Agreement with LG Chem for Novel Treatments for Type 2 Diabetes and Osteoarthritis in Latin America
